Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a randomised, double-blind, placebo-controlled trial.

ABSTRACT:

Objective

To investigate whether treatment with oral corticosteroids and intravenous immunoglobulin (IVIg) improves pregnancy outcomes in women with unexplained recurrent pregnancy loss (RPL) following assisted reproduction technology (ART) treatment.

Design

A randomised, double-blinded, parallel-group, placebo-controlled trial conducted from January 2021 to February 2024.

Setting

A single-centre trial at a Danish tertiary clinic for RPL management.

Participants

80 women with at least two consecutive early pregnancy losses following ART, age 18-41 years, body mass index below 35, and no identified cause of RPL. Forty participants were allocated to each group, with 37 fulfilling the protocol criteria in each group.

Interventions

Participants were randomis

SUBMITTER: Norgaard-Pedersen C 

PROVIDER: S-EPMC12636943 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature